New Acting CEO in Vitrolife

New Acting CEO in Vitrolife Dr. Magnus Nilsson, now Deputy CEO of Vitrolife AB, has today been appointed Acting CEO. The process of finding a permanent CEO has been initiated by the Board of Directors of Vitrolife. Former CEO Dr. Peter Svalander will remain in the company. Dr. Svalander has during the past six months worked from Denver, Colorado, USA, home of the American branch of Vitrolife. He will to a larger extent focus on the introduction and sales work that is ongoing with the newly developed product line for in vitro fertilisation (IVF), the GIII Series. The GIII Series - Closer to Nature, was approved for sales by the American Food and Drug Administration (FDA) on September 11, 2002. The official launch was at the Annual Meeting of the American Society for Reproductive Medicine, in October 2002. Gothenburg, Sweden, January 3, 2003 The Board of Directors, Vitrolife AB For further information, please contact: Acting CEO, Dr. Magnus Nilsson Phone: + 46 31 721 80 00 Mobile phone: + 46 708 22 80 61 Chairman of the Board, Patrik Tigerschiöld Phone: + 46 8 614 00 20 www.vitrolife.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/01/03/20030103BIT00280/wkr0001.doc http://www.waymaker.net/bitonline/2003/01/03/20030103BIT00280/wkr0002.pdf